Engineered Natural Membrane Vesicle Exosomes as a Torin2 Delivery Platform for Targeted Therapy of Anaplastic Thyroid Carcinoma.
- 1Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China.
- 2Department of Radiology, Qingdao Women and Children's Hospital, Qingdao, Shandong, People's Republic of China.
Abstract
Background
Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy with poor prognosis due to rapid progression and resistance to conventional therapies. Integrin αvβ3 is overexpressed in ATC, making it a promising target. Torin2, a potent mTOR inhibitor, shows antitumor activity but suffers from poor solubility, short half-life, and systemic toxicity. Exosomes offer a natural delivery platform but lack intrinsic tumor tropism. This study aimed to develop iRGD-modified engineered exosomes for targeted delivery of Torin2 to ATC cells.Methods
iRGD-modified exosomes (iRGD-Exos) were generated by transducing HEK-293T cells with a lentiviral vector (EGFP-C1-iRGD-Lamp2b) encoding a fusion protein of enhanced green fluorescent protein (EGFP) and iRGD peptide fused to the N-terminus of lysosomal-associated membrane protein 2b (Lamp2b), a transmembrane protein naturally enriched on exosome surfaces. Torin2 was loaded into iRGD-Exos via electroporation (Torin2@iRGD-Exos). The nanoparticles were characterized for size, morphology, loading efficiency, and stability. Cellular uptake was evaluated in ATC cell lines using flow cytometry and confocal microscopy. In vitro cytotoxicity was assessed by live/dead staining. In vivo antitumor efficacy and biosafety were examined in BHT101 xenograft-bearing nude mice.Results
iRGD-Exos and Torin2@iRGD-Exos exhibited spherical morphology, appropriate size, and a loading efficiency of 23.68%. iRGD modification significantly enhanced exosome uptake by ATC cells compared to unmodified exosomes. Torin2@iRGD-Exos showed superior in vitro cytotoxicity relative to free Torin2 or Torin2@blank-Exos. In vivo, Torin2@iRGD-Exos markedly suppressed tumor growth without causing significant body weight loss or organ toxicity compared to free Torin2.Conclusion
The iRGD-modified exosomal delivery system (Torin2@iRGD-Exos) achieves efficient tumor targeting, excellent biocompatibility, and potent antitumor activity against ATC both in vitro and in vivo, offering a promising therapeutic strategy for integrin αvβ3-overexpressing malignancies.
Related
- Exosomes in regenerative medicine from biological messengers to engineered nanocarriers for precision therapeutics
- Engineered Brain‐Targeted Exosomes Delivering FGF1 for Sustained Glycemic Regulation and Multitarget Neurovascular Protection in Diabetic Stroke
- Bone-targeting engineered exosomes delivering teriparatide mRNA for the treatment of osteoporosis.
- Biomimetic and Natural Exosomes in Drug Delivery: A Critical Review.
- Engineering exosomes-mediated RNA delivery regulates bone homeostasis and alleviates osteoporosis.
BibTeX
@article{wang2026engineered,
title = {{Engineered Natural Membrane Vesicle Exosomes as a Torin2 Delivery Platform for Targeted Therapy of Anaplastic Thyroid Carcinoma.}},
author = {Congcong Wang and Xiaonian Zhang and Guohua Qin and Peihang Han and Yutian Li and Xufu Wang},
journal = {International journal of nanomedicine},
year = {2026},
month = oct,
doi = {10.2147/ijn.s633252},
url = {https://europepmc.org/article/MED/42948446},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Engineered Natural Membrane Vesicle Exosomes as a Torin2 Delivery Platform for Targeted Therapy of Anaplastic Thyroid Carcinoma.
AU - Congcong Wang
AU - Xiaonian Zhang
AU - Guohua Qin
AU - Peihang Han
AU - Yutian Li
AU - Xufu Wang
PY - 2026
DA - 2026/10/23
JO - International journal of nanomedicine
DO - 10.2147/ijn.s633252
UR - https://europepmc.org/article/MED/42948446
AB - Background Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy with poor prognosis due to rapid progression and resistance to conventional therapies. Integrin αvβ3 is overexpressed in ATC, making it a promising target. Torin2, a potent mTOR inhibitor, shows antitumor activity but suffers from poor solubility, short half-life, and systemic toxicity. Exosomes offer a natural delivery platform but lack intrinsic tumor tropism. This study aimed to develop iRGD-modified engineered exosomes for targeted delivery of Torin2 to ATC cells.Methods iRGD-modified exosomes (iRGD-Exos) were generated by transducing HEK-293T cells with a lentiviral vector (EGFP-C1-iRGD-Lamp2b) encoding a fusion protein of enhanced green fluorescent protein (EGFP) and iRGD peptide fused to the N-terminus of lysosomal-associated membrane protein 2b (Lamp2b), a transmembrane protein naturally enriched on exosome surfaces. Torin2 was loaded into iRGD-Exos via electroporation (Torin2@iRGD-Exos). The nanoparticles were characterized for size, morphology, loading efficiency, and stability. Cellular uptake was evaluated in ATC cell lines using flow cytometry and confocal microscopy. In vitro cytotoxicity was assessed by live/dead staining. In vivo antitumor efficacy and biosafety were examined in BHT101 xenograft-bearing nude mice.Results iRGD-Exos and Torin2@iRGD-Exos exhibited spherical morphology, appropriate size, and a loading efficiency of 23.68%. iRGD modification significantly enhanced exosome uptake by ATC cells compared to unmodified exosomes. Torin2@iRGD-Exos showed superior in vitro cytotoxicity relative to free Torin2 or Torin2@blank-Exos. In vivo, Torin2@iRGD-Exos markedly suppressed tumor growth without causing significant body weight loss or organ toxicity compared to free Torin2.Conclusion The iRGD-modified exosomal delivery system (Torin2@iRGD-Exos) achieves efficient tumor targeting, excellent biocompatibility, and potent antitumor activity against ATC both in vitro and in vivo, offering a promising therapeutic strategy for integrin αvβ3-overexpressing malignancies.
SN - 1176-9114
SN - 1178-2013
ER -